Anavex Life Sciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Anavex Life Sciences

AVXL 7.740

-2.9%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ImGettingBetter	7/11/2022 11:59:10 PM
	of 120

The Petri Dish: FDA to fast-track Biogen's next Alzheimer's drug bizjournals.com ------- Well this article is a few days old, but it has been a little over a year ago Biogen was able to get the FDA to approve Aduhelm. So now they have fast tracked Lecanemab and according to this article the FDA will provide a decision on 6 Jan 2023. That doesn't seem possible. Sounds like money at work, not science. I wanted to place this article as an artifact on 6 Jan 2023. From the article - Aduhelm targets a different form of amyloid than lecanemab does. Lecanemab is now in Phase 3 trials, with data expected in the third quarter of this year, which will likely be pivotal in the FDA's assessment of the drug. The agency will issue its final decision on lecanemab on Jan. 6.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next